| 1 |
Treatment of HCV Infection by Targeting MicroRNA
Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz et al. · New England Journal of Medicine
Open access |
27 Mar 2013 |
2,233 |
| 2 |
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al. · New England Journal of Medicine
|
23 Apr 2013 |
1,794 |
| 3 |
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
Thomas C. C. Yau et al. · JAMA Oncology
Open access |
Oct 2020 |
1,243 |
| 4 |
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients
Francesca J. Torriani, Maribel Rodriguez‐Torres, Jürgen Kurt Rockstroh et al. · New England Journal of Medicine
Open access |
28 Jul 2004 |
1,238 |
| 5 |
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark Sulkowski et al. · New England Journal of Medicine
|
15 Jan 2014 |
1,197 |
| 6 |
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al. · New England Journal of Medicine
Open access |
23 Apr 2013 |
1,093 |
| 7 |
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
David R. Nelson et al. · Hepatology
Open access |
23 Jan 2015 |
694 |
| 8 |
Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C
John G. McHutchison, Geoffrey M Dusheiko, Mitchell L. Shiffman et al. · New England Journal of Medicine
|
28 Nov 2007 |
451 |
| 9 |
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al. · The Lancet Infectious Diseases
|
15 Mar 2013 |
331 |
| 10 |
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark Sulkowski, Susanna Naggie, Jacob Paul Lalezari et al. · JAMA
Open access |
19 Jul 2014 |
254 |
| 11 |
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Masatoshi Kudo, Ana María Matilla, Armando Santoro et al. · Journal of Hepatology
Open access |
26 May 2021 |
234 |
| 12 |
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
Meike H. van der Ree, Adriaan J. van der Meer, Joep de Bruijne et al. · Antiviral Research
|
8 Sep 2014 |
202 |
| 13 |
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gregory T. Everson et al. · Gastroenterology
Open access |
30 Oct 2013 |
199 |
| 14 |
Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C
Maribel Rodriguez‐Torres, Lennox J. Jeffers, Muhammad Y. Sheikh et al. · New England Journal of Medicine
|
14 Jan 2009 |
182 |
| 15 |
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
Richard E. Nettles, Min Gao, Marc Bifano et al. · Hepatology
Open access |
Dec 2010 |
177 |
| 16 |
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
Andrew Joseph Muir et al. · Journal of Hepatology
|
23 Jul 2014 |
147 |
| 17 |
High-resolution mapping of forest carbon stocks in the Colombian Amazon
Gregory P. Asner, John K. Clark, Joseph Mascaro et al. · Biogeosciences
Open access |
25 Jul 2012 |
144 |
| 18 |
Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
Nezam H. Afdhal, Geoffrey M Dusheiko, Edoardo Giovanni Giannini et al. · Gastroenterology
Open access |
11 Oct 2013 |
143 |
| 19 |
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
Eric Lawitz, Maribel Rodriguez‐Torres, Andrew Joseph Muir et al. · Journal of Hepatology
|
30 Apr 2008 |
128 |
| 20 |
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
Paul J. Pockros, Lennox J. Jeffers, Nezam H. Afdhal et al. · Hepatology
Open access |
26 Feb 2007 |
112 |
| 21 |
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
Maribel Rodriguez‐Torres, Eric Lawitz, Kris V. Kowdley et al. · Journal of Hepatology
|
23 Nov 2012 |
107 |
| 22 |
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
Patrick Marcellin, Hugo Cheinquer, Manuela Curescu et al. · Hepatology
|
18 Jun 2012 |
105 |
| 23 |
R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†
Paul J. Pockros, David R. Nelson, Eliot W. Godofsky et al. · Hepatology
Open access |
20 Jun 2008 |
101 |
| 24 |
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
Fred F Poordad et al. · JAMA
|
5 May 2015 |
95 |
| 25 |
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Ignacio Melero et al. · Annals of Oncology
Open access |
22 May 2024 |
94 |
| 26 |
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
David R. Nelson, Yves Benhamou, Wan‐Long Chuang et al. · Gastroenterology
Open access |
2 Jul 2010 |
93 |
| 27 |
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
John G. McHutchison, Zachary D Goodman, Keyur Patel et al. · Gastroenterology
Open access |
17 Dec 2009 |
93 |
| 28 |
Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels
Mitchell L. Shiffman, M. Diago, Albert Tran et al. · Clinical Gastroenterology and Hepatology
|
May 2006 |
91 |
| 29 |
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
Alexander J. V. Thompson, Keyur Patel, Wan‐Long Chuang et al. · Gut
Open access |
26 Aug 2011 |
89 |
| 30 |
Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics
Michael Fried, Donald M. Jensen, Maribel Rodriguez‐Torres et al. · Hepatology
Open access |
9 Jun 2008 |
77 |
| 31 |
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin
Norbert Bräu, Maribel Rodriguez‐Torres, Dale Prokupek et al. · Hepatology
Open access |
26 Mar 2004 |
74 |
| 32 |
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Thomas C. C. Yau, Vittorina Zagonel, Armando Santoro et al. · Journal of Clinical Oncology
Open access |
13 Dec 2022 |
70 |
| 33 |
Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive A 16-Week Abbreviated Course of Peginterferon Alfa-2A (40Kd) Plus Ribavirin
M. Diago, Mitchell L. Shiffman, Jean–Pierre Bronowicki et al. · Hepatology
Open access |
27 Jan 2010 |
68 |
| 34 |
Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial
Maribel Rodriguez‐Torres, Jihad Slim, Laveeza Bhatti et al. · HIV Clinical Trials
Open access |
Jun 2012 |
65 |
| 35 |
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1
Stefan Zeuzem, Mark Sulkowski, Eric Lawitz et al. · Gastroenterology
|
2 Jul 2010 |
64 |
| 36 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Edward John Gane et al. · Gastroenterology
Open access |
31 Jul 2016 |
60 |
| 37 |
A phase 1, randomized, dose‐ranging study of GS ‐5816, a once‐daily NS 5A inhibitor, in patients with genotype 1–4 hepatitis C virus
Eric Lawitz, Bradley Freilich, John O. Link et al. · Journal of Viral Hepatitis
Open access |
16 Jul 2015 |
58 |
| 38 |
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study
Michael Peter Manns, Edward John Gane, Maribel Rodriguez‐Torres et al. · Hepatology
Open access |
3 Apr 2012 |
58 |
| 39 |
1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL
Peter Ferenci et al. · Journal of Hepatology
|
Apr 2013 |
54 |
| 40 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Tudor–Eliade Ciuleanu, Igor S. Bazin, Dan Lungulescu et al. · Annals of Oncology
Open access |
23 Jan 2016 |
52 |
| 41 |
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( )
David R. Nelson, Stefan Zeuzem, Pietro Andreoné et al. · Annals of Hepatology
Open access |
2012 |
52 |
| 42 |
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Claudio Pasquinelli et al. · Antimicrobial Agents and Chemotherapy
Open access |
31 Jan 2012 |
51 |
| 43 |
Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938
Jérémie Guedj, Phillip S. Pang, Jill Denning et al. · Antiviral Therapy
|
24 Jan 2014 |
50 |
| 44 |
Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients
Patrick Marcellin, Robert G. Gish, Norman Gitlin et al. · Journal of Hepatology
|
24 Oct 2009 |
46 |
| 45 |
All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection
David L. Wyles, Maribel Rodriguez‐Torres, Eric Lawitz et al. · Hepatology
Open access |
5 Feb 2014 |
45 |
| 46 |
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
Maribel Rodriguez‐Torres, Mark Sulkowski, Raymond T. Chung et al. · Journal of Viral Hepatitis
Open access |
6 Aug 2009 |
44 |
| 47 |
Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients
Heiner H. Wedemeyer, Donald M. Jensen, Robert Herring et al. · Hepatology
|
24 Jan 2013 |
43 |
| 48 |
Effect of Cryopreservation on Human Articular Chondrocyte Viability, Proliferation, and Collagen Expression
E. Rendal, Emilia Maneiro-Pampı́n, M. Rodríguez-Cabarcos et al. · Cryobiology
|
Feb 2001 |
42 |
| 49 |
Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study
Maribel Rodriguez‐Torres, Francesca J. Torriani, Vincent Soriano et al. · Antimicrobial Agents and Chemotherapy
Open access |
27 Sep 2005 |
41 |
| 50 |
High Eradication Rates of Helicobacter pylori Infection with First- and Second-Line Combination of Esomeprazole, Tetracycline, and Metronidazole in Patients Allergic to Penicillin
Maribel Rodr�guez-Torres, Rosa Salgado-Mercado, Carlos F. R�os-Bedoya et al. · Digestive Diseases and Sciences
|
31 Mar 2005 |
41 |